AA
EUCRW

Ancora Advisors’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Ancora Advisors’s Portfolio EUCRW Stock Details EUCRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47
Closed – – 2182
2022
Q4 		$0 Hold
47
– – ﹤0.01% 2224
2022
Q3 		$0 Hold
47
– – ﹤0.01% 2362
2022
Q2 		$0 Hold
47
– – ﹤0.01% 2522
2022
Q1 		$0 Buy
+47
New +$19 ﹤0.01% 2695

Other funds holding EUCRW

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ancora Advisors's EUCRW Position: Q1 2023 in Review

Ancora Advisors sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q1 2023, closing a stake of 47 shares.

Ancora Advisors first reported a position in EUCRW in Q1 2022 and held it in 4 quarters. The position peaked at $0 in Q4 2022. 22 funds tracked by Wall St. Rank hold EUCRW as of Q1 2023.

  • Ancora Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
  • Ancora Advisors sold 47 Eucrates Biomedical Acquisition Corp. Warrant shares in Q1 2023.
  • Ancora Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2022 and held it in 4 quarters.
  • Ancora Advisors's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $0 in Q4 2022.
  • 22 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q1 2023.

Based on Ancora Advisors's 13F filing for Q1 2023, filed 16 May 2023.